Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1255-1262

  Zamboni, William C ^a,b,c,d   Combest, Austin J ^a   Deloia, Julie A ^e   Edwards, Robert P ^e   Bridges, Arlene S ^f   Zamboni, Beth A ^g   Walko, Christine M ^a,b   Yu, Angela Y C ^a   Krivak, Thomas C ^e   Kelley, Joseph L ^e  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Carolina Center of Cancer Nanotechnology Excellence   (United States)

^d North Carolina Biomedical Innovation Network   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g CARLOW UNIVERSITY   (United States)

Author keywords

CA 125; Docetaxel; Midazolam; Ovarian cancer; Pharmacogenomics; Pharmacokinetics

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; MIDAZOLAM;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ATP BINDING CASSETTE SUBFAMILY B MEMBER 1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 3A5 GENE; DIARRHEA; DRUG CLEARANCE; DRUG ELIMINATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; MARKER GENE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHARMACOGENETICS; PHENOTYPIC VARIATION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHROMATOGRAPHY, LIQUID; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TAXOIDS;

EID: 82455175240     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1609-9     Document Type: Article

References (24)

1. A Gadducci S Cosio R Tana, et al. 2009 Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer Crit Rev Oncol Hematol 69 12 27 18595727 10.1016/j.critrevonc.2008.05.001
2. RF Ozols BN Bundy J Fowler, et al. 1999 Randomized phase III study of cisplatin (CIS) paclitaxel versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a gynecologic oncology group trial (GOG 158) Proc Am Soc Clin Oncol 18 356a
3. DA Vorobiof BL Rapoport MR Chasen, et al. 2003 Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy Int J Gynecol Cancer 13 287 291 12801257 10.1046/j.1525-1438.2003.13203.x 1:STN:280: DC%2BD3s3nsFeiug%3D%3D (Pubitemid 38222575)
4. PA Vasey GC Jayson A Gordon, et al. 2004 Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 1682 1691 15547181 10.1093/jnci/djh323 1:CAS:528:DC%2BD2cXhtVSqsrzJ (Pubitemid 39585637)
5. JI Lee C Chaves-Gnecco JA Amico, et al. 2002 Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping Clin Pharmacol Ther 72 718 727 12496753 10.1067/mcp.2002. 129068 1:CAS:528:DC%2BD3sXlt1SisA%3D%3D (Pubitemid 36021011)
6. BH Goh SC Lee LZ Wang, et al. 2002 Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J Clin Oncol 20 3683 3690 12202670 10.1200/JCO.2002.01.025 1:CAS:528:DC%2BD38XntVynsrc%3D (Pubitemid 34983229)
7. ER Lepper SD Baker M Permenter, et al. 2005 Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients Clin Cancer Res 11 7398 7404 16243813 10.1158/1078-0432.CCR-05-0520 1:CAS:528:DC%2BD2MXhtFartbvM (Pubitemid 41507700)
8. TM Bosch AD Huitema VD Doodeman, et al. 2006 Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel Clin Cancer Res 12 5786 5793 17020985 10.1158/1078-0432.CCR-05-2649 1:CAS:528:DC%2BD28XhtVartbjM (Pubitemid 44629610)
9. S Marsh Jl Pau CR King G Gifford HL McLeod R Brown 2007 Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer J Clin Oncol 25 4528 4535 17925548 10.1200/JCO.2006.10.4752 1:CAS:528:DC%2BD2sXht1yhsr7P (Pubitemid 350035308)
10. JD Allen RF Brinkhuis L van Deemter, et al. 2000 Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance Cancer Res 60 5761 5766 11059771 1:CAS:528:DC%2BD3cXnvVSntrg%3D
11. L Van Zuylen A Sparreboom A Van der Gaast, et al. 2002 Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933 Eur J Cancer 38 1090 1099 12008197 10.1016/S0959-8049(02)00035-7 (Pubitemid 34468014)
12. A Tran V Jullien J Alexandre, et al. 2006 Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther 79 570 580 16765145 10.1016/j.clpt.2006.02.003 1:CAS:528:DC%2BD28Xltl2msrc%3D (Pubitemid 43833447)
13. SD Baker J Verweij GA Cusatis, et al. 2009 pharmacogenetic pathway analysis of docetaxel elimination Clin Pharmacol Ther 85 155 163 18509327 10.1038/clpt.2008.95 1:CAS:528:DC%2BD1MXmt1Cquw%3D%3D
14. D Isla C Sarries R Rosell, et al. 2004 Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann Oncol 15 1194 1203 15277258 10.1093/annonc/mdh319 1:STN:280: DC%2BD2cznt1Wmtw%3D%3D (Pubitemid 39199306)
15. W Hou JW Watters HL McLeod 2004 Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography- tandem mass spectrometry J Chromatogr B Anal Technol Biomed Life Sci 804 263 267 10.1016/j.jchromb.2004.01.021 1:CAS:528:DC%2BD2cXjtVOjtLw%3D (Pubitemid 38481700)
16. RA Parise RR Ramanathan WC Zamboni MJ Egorin 2003 Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma J Chromatogr Anal Technol Biomed Life Sci 783 231 236 10.1016/S1570-0232(02)00659-1 1:CAS:528:DC%2BD3sXosFyhsQ%3D%3D (Pubitemid 35351650)
17. JT Kapron E Pace CK Van Pelt, et al. 2003 Quantitation of midazolam in human plasma by automated chip-based infusion nanoelectrospray tandem mass spectrometry Rapid Commun Mass Spectrom 17 2019 2026 12955729 10.1002/rcm.1145 1:CAS:528:DC%2BD3sXntlamu7w%3D (Pubitemid 37093076)
18. S Marsh CR King AA Garsa HL McLeod 2005 Pyrosequencing of clinically relevant polymorphisms Methods Mol Bio 311 91 114
19. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors JNCI 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
20. WT Beatrice A Dnistrian O Lloyd 2002 Ovarian cancer antigen CA125 is encoded by the MUC16 Mucin gene Int J Cancer 98 737 740 10.1002/ijc.10250 (Pubitemid 34225625)
21. M Epiney C Bertossa A Weil A Campana P Bischof 2000 CA125 production by the peritoneum: in vitro and in vivo studies Human Prod 15 1261 1265 1:CAS:528:DC%2BD3cXksVCltbk%3D (Pubitemid 30335947)
22. SM Crawford J Peace 2005 Does the CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16 47 50 15598937 10.1093/annonc/mdi012 1:STN:280:DC%2BD2cnitlSquw%3D%3D (Pubitemid 40124477)
23. JM Riedinger F Bonnetain JP Basuyau, et al. 2007 Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome Ann Oncol 18 881 885 17301071 10.1093/annonc/mdl500 1:STN:280:DC%2BD2s3ns1Kluw%3D%3D (Pubitemid 47054085)
24. M Teeling P McGing DN Carney 1989 The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer Ir J Med Sci 158 59 62 2745033 10.1007/BF02942143 1:STN:280:DyaL1MzgslyqtQ%3D%3D (Pubitemid 19114141)